Ghrelin, paraoxonase and arylesterase levels in depressive patients before and after citalopram treatment

dc.contributor.authorBarim, Abdullah Onder
dc.contributor.authorAydin, Suleyman
dc.contributor.authorColak, Ramis
dc.contributor.authorDag, Ersel
dc.contributor.authorDeniz, Omer
dc.contributor.authorSahin, Ibrahim
dc.date.accessioned2026-08-12T17:30:13Z
dc.date.issued2009
dc.departmentFırat Üniversitesi
dc.description.abstractObjectives: The purpose of this study was to examine alterations in lipid profiles and in the serum concentrations of acylated and desacylated ghrelin, paraoxonase and arylesterase in psychiatric patients before and after treatment with 40 mg citalopram daily for 3 months. Design and methods: Samples were collected from 22 healthy controls and 24 psychiatric patients before and after citalopram treatment. Blood levels of acylated and desacylated ghrelin were measured by radioimmunoassay. Paraoxonase and arylesterase activities were determined spectrophotometrically. Lipid parameters were measured on the OLYMPUS-AU400. Results: It was found that the levels of acylated, desacylated ghrelin, paraoxonase arylesterase, total cholesterol and triglyceride were lower in depressive patients before citalopram treatment than in the control group. Those parameters were not restored after citalopram treatment except for the arylesterase level. Conclusion: Decreased PON1 and ghrelin levels as well as fluctuations in lipid profiles may be involved in the etiology of depressive disorders. (c) 2009 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
dc.description.sponsorshipFUBAP [1332]; TUBITAK [106S350]
dc.description.sponsorshipThis study, which is a master's thesis, was partly sponsored by project number 1332 of FUBAP and partly utilized materials remaining from project number 106S350 of TUBITAK. The authors express their gratitude to both institutions.
dc.identifier.doi10.1016/j.clinbiochem.2009.02.020
dc.identifier.endpage1081
dc.identifier.issn0009-9120
dc.identifier.issn1873-2933
dc.identifier.issue10.Kas
dc.identifier.pmid19272368
dc.identifier.scopus2-s2.0-67349287047
dc.identifier.scopusqualityQ2
dc.identifier.startpage1076
dc.identifier.urihttps://doi.org/10.1016/j.clinbiochem.2009.02.020
dc.identifier.urihttps://hdl.handle.net/11508/56018
dc.identifier.volume42
dc.identifier.wosWOS:000267274300023
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherPergamon-Elsevier Science Ltd
dc.relation.ispartofClinical Biochemistry
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectGhrelin
dc.subjectParaoxonase
dc.subjectArylesterase
dc.subjectMajor depression
dc.titleGhrelin, paraoxonase and arylesterase levels in depressive patients before and after citalopram treatment
dc.typeArticle

Dosyalar